5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001

被引：16

作者：

Hamid, Omid

Robert, Caroline

Daud, Adil

Hodi, F. Stephen

Hwu, Wen-Jen

Kefford, Richard

Wolchok, Jedd D.

Hersey, Peter

Joseph, Richard Wayne

Weber, Jeffrey S.

Dronca, Roxana Stefania

Mitchell, Tara C.

Patnaik, Amita

Zarour, Hassane M.

Joshua, Anthony M.

Jensen, Erin

Ibrahim, Nageatte

Ahsan, Sama

Ribas, Antoni

机构：

[1] Angeles Clin & Res Inst, Los Angeles, CA USA

[2] Gustave Roussy, Villejuif, France

[3] Univ Calif San Francisco, San Francisco, CA USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[6] Westmead Hosp & Melanoma Inst, Macquarie Pk, Westmead, NSW, Australia

[7] Mem Sloan Kettering Canc Ctr, New York, NY USA

[8] Univ Sydney, Centenary Inst, Sydney, NSW, Australia

[9] Mayo Clin Canc Ctr Florida, Jacksonville, FL USA

[10] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[11] Mayo Clin, Rochester, MN USA

[12] Univ Penn, Philadelphia, PA USA

[13] South Texas Accelerated Res Therapeut, San Antonio, TX USA

[14] Univ Pittsburgh Canc Inst, Pittsburgh, PA USA

[15] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] Merck Co Inc, Kenilworth, NJ USA

[17] Univ Calif Los Angeles, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9516

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9516

引用

页数：1